5th Optimizing Hybrid Clinical Trials Summit
The 5th Optimizing Hybrid Clinical Trials Summit (September 11-12, 2024 | Boston, MA) is uniting stakeholders in Clinical Operations, Innovation, Procurement and Digital Health and more to share practical case studies in building a budget and financial business case to run DCTs, securing end-to-end data flow, and managing data integrity and quality to operationalize hybrid trials.
Join 80+ senior stakeholders including Pfizer, Bayer, Eli Lilly & Co, Astellas, UCB, AbbVie and more to explore strategies to optimize hybrid clinical trials and enhance DE&I and patient access, improve operational efficiency and leverage remote data collection to demonstrate efficacy and safety in DCTs.
Be the first to see the brand-new Event Guide with our star speaker faculty here: https://ter.li/m9019q.
Why attend?
- Explore case studies to gain approval from internal executives to initiate a hybrid clinical trial
- Examine ways to streamline and negotiate site coordinator costs to identify cost-saving incentives when running a hybrid clinical trial
- Create cost efficiencies through strategic sourcing and procurement to elevate ROI and strengthen vendor relationships
- Overcoming data centralization issues faced by clinical trial sites when adopting digital endpoints
- Use pilot-scale strategy for assessing implementation of novel technology to improve patient experience and engagement in hybrid clinical trials
Best of all, it’s FREE TO ATTEND for drug developers!
Find out more here: https://ter.li/m9019q.
